Please assess the completion status of the following clinical trial:

Trial Title: Iloprost Effects on Gas Exchange and Pulmonary Mechanics

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Pulmonary hypertension as evidenced by:~   * In patients with a pulmonary artery catheter, a mean pulmonary arterial pressure greater then 25 mmHg with a pulmonary capillary wedge pressure less than or equal to 15 mmHg, or~  * Echocardiographic evidence of pulmonary arterial hypertension including~     * a PA systolic pressure greater than 35 mmHg, or~    * in those patients in whom a PA systolic cannot be estimated for technical reasons, RV dilatation and/or decreased RV function in the presence of normal LV function.~2. ARDS/ALI as indicated by:~   * Diffuse pulmonary infiltrates involving at least three of four quadrants on chest x-ray.~  * PaO2/FIO2 less than 300 while on mechanical ventilation.~  * Recognized cause of ARDS/ALI~  * Absence of clinical evidence of left atrial hypertension~3. presence of an arterial line for pressure monitoring and blood sampling, and~4. the ability to obtain informed consent from the patient or next of kin.~Exclusion Criteria:~1. clinical instability as evidenced by changes in ventilator settings or medications within the preceding hour, and~2. presence of left ventricular dysfunction and/or left atrial enlargement by cardiac echo, or catheterization,~3. Liver failure (Child-Pugh Class B or C)~4. Renal failure on dialysis~5. Pregnancy: all females of child-bearing potential will have a negative pregnancy test before being allowed to enroll~6. Systolic blood pressure less than 85 mm Hg or the need for pressors in the first 10 patients; after review of the first 10 patients by the DMSB, patients on norepinephrine (without additional pressors) in doses less than 0.2 mcg/kg/min may be enrolled if the DMSB finds no evidence of iloprost induced systemic hypotension in the first 10 patients~7. Thrombocytopenia, bleeding diathesis or active bleeding~8. Asthma/Severe bronchospasm~9. Age \< 18 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Iloprost (Type: EXPERIMENTAL): All patients will have their response to Iloprost compared to baseline pre-treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).